SAN DIEGO, Feb. 18 /PRNewswire/ -- Johns Hopkins Medicine has become the latest academic medical center to acquire the Naviscan Positron Emission Mammography (PEM) scanner. The device will be utilized by Richard Wahl, M.D., F.A.C.R, Professor of Radiology and Nuclear Medicine at the Johns Hopkins University School of Medicine, in pre-clinical and translational research for the development of novel radiotracers.
"As the use of Naviscan's organ-specific PET imaging technology continues to be used in cutting-edge breast cancer research and clinical patient management, Naviscan is also developing its use in new clinical applications. As a result, the development and clinical validation of novel radiotracers is essential," said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc.
Dr. Wahl patented the technology which enabled Naviscan to develop the first and only FDA-cleared PET-guided biopsy accessory, known as Stereo Navigator®. Naviscan obtained an exclusive license to this patent, which Wahl developed while he was at the University of Michigan.
Other academic medical centers utilizing Naviscan's PEM technology include University of Cincinnati, Baylor University, M.D. Anderson, University of Chicago, and the Boston University Medical Center.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.
SOURCE Naviscan, Inc.
|SOURCE Naviscan, Inc.|
Copyright©2010 PR Newswire.
All rights reserved